insights_auto
Waarom is RARE gedaald 4,30%?
Meer informatiechevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$ 16,48
arrow_downward
-4,30%(-0,74) 1D
US$ 16,50
arrow_upward
+0,12% (+0,020)bedtimeNa sluitingstijd
Gesloten: 20 nov, 16:00:03 GMT-5 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor RARE genereren…
Openen
US$ 16,94
Hoog
US$ 17,35
Laag
US$ 16,42
Beursw.
1,68 mld.
Gem. vol.
3,67 mln.
Volume
3,01 mln.
52 wk hoog
US$ 39,89
52 wk laag
US$ 12,73
WPA
US$ -5,19
Bèta
0,37
Uitstaande aandelen
101,92 mln.
Aantal medewerkers
1K
Openen
US$ 16,94
Hoog
US$ 17,35
Laag
US$ 16,42
Beursw.
1,68 mld.
Gem. vol.
3,67 mln.
Volume
3,01 mln.
52 wk hoog
US$ 39,89
52 wk laag
US$ 12,73
WPA
US$ -5,19
Bèta
0,37
Uitstaande aandelen
101,92 mln.
Aantal medewerkers
1K
Nieuwsartikelen
Van webbronnen en nieuwspartners
AP News
·
1 dag geleden
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
The Motley Fool
·
4 uur geleden
The S&P 500 Is 14 for 14 After Midterm Elections. Here’s How I’d Invest Now.
Beinsure
·
18 uur geleden
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
WSJ
·
2 dagen geleden
Dow, S&P 500 Poised to Close at a Correction
Profiel
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Over Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Medewerkers1,37K
Opgericht2010
HoofdkantoorNovato, Californië, Verenigde Staten
SectorHealth Care
Industrie-
Websiteultragenyx.com